MAP2K7 and melanoma: Zhou et al. showed that high expression of CSNK2A1 leads to increased resistance to RAF-MEK kinase inhibitors (trametinib, vemurafenib, and dabrafenib) by sustaining ERK phosphorylation in BRAF-mutated melanoma cells.